Her-2 positive mucinous carcinoma breast cancer, case report

Gabriela Sofia Gomez Macias; Margarita Lilia Garza Montemayor

Her-2 positive mucinous carcinoma breast cancer, case report

dc.creator	Gabriela Sofia Gomez Macias
dc.creator	Margarita Lilia Garza Montemayor
dc.date	2018
dc.date.accessioned	2018-10-18T15:34:03Z
dc.date.available	2018-10-18T15:34:03Z
dc.description	Introduction Mucinous carcinoma is a variant of invasive breast carcinomas that accounts for 2% of them and has a better prognosis in contrast to the non-specific invasive carcinoma. They regularly are positive for estrogen and progesterone receptors and, generally, they do not overexpress HER2. When HER2 is positive, the first line treatment is trastuzumab; although the resistance is 52–89% for the non-specific carcinoma, it has been described just once in mucinous carcinoma. Case summary A 48-year-old female presented with a lump in her right breast and after a biopsy, it was diagnosed as mucinous carcinoma in the core biopsy and surgical resection, with positive hormone receptors and HER2 positive (3+) in 100% of the tumor cells. She was treated with neoadjuvant chemotherapy based on trastuzumab and pertuzumab with no pathological response. Discussion There are few pure mucinous carcinomas positive for HER2. Mucinous carcinomas are positive for HER2 account for less than 5% of invasive ductal carcinoma. Furthermore, our case was resistance to chemotherapy. Most mucinous carcinomas test negative for HER2, so they usually would not be treated with trastuzumab, in this case because the expression of HER2 in the biopsies we initiated it. Conclusion It's important to know that cases of mucinous carcinoma positive for HER2 exist and to be aware of the clinical problems that they may present: resistance to trastuzumab. Also, we need to understand the responsible mechanisms of this resistance and use immunohistochemistry for MUC which may predict it. © 2017
dc.identifier.doi	10.1016/j.ijscr.2017.12.025
dc.identifier.endpage	246
dc.identifier.issn	22102612
dc.identifier.startpage	242
dc.identifier.uri	http://hdl.handle.net/11285/630252
dc.identifier.volume	42
dc.language	eng
dc.publisher	Elsevier Ltd
dc.relation	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85039702099&doi=10.1016%2fj.ijscr.2017.12.025&partnerID=40&md5=85dd92ef794ab544f3f3f18e3ba8927b
dc.relation	Investigadores
dc.relation	Estudiantes
dc.rights	info:eu-repo/semantics/openAccess
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0
dc.source	International Journal of Surgery Case Reports
dc.subject	epidermal growth factor receptor 2
dc.subject	estrogen receptor
dc.subject	mucin
dc.subject	pertuzumab
dc.subject	progesterone receptor
dc.subject	trastuzumab
dc.subject	adult
dc.subject	Article
dc.subject	breast biopsy
dc.subject	cancer adjuvant therapy
dc.subject	cancer cell
dc.subject	cancer combination chemotherapy
dc.subject	cancer diagnosis
dc.subject	cancer grading
dc.subject	cancer hormone therapy
dc.subject	cancer size
dc.subject	cancer surgery
dc.subject	case report
dc.subject	cell size
dc.subject	clinical article
dc.subject	clinical feature
dc.subject	colloid carcinoma
dc.subject	cytoplasm
dc.subject	drug treatment failure
dc.subject	eosinophil
dc.subject	family history
dc.subject	female
dc.subject	human
dc.subject	human cell
dc.subject	human epidermal growth factor receptor 2 positive breast cancer
dc.subject	immunohistochemistry
dc.subject	middle aged
dc.subject	neoadjuvant chemotherapy
dc.subject	priority journal
dc.subject	sentinel lymph node biopsy
dc.subject	simple mastectomy
dc.subject	surgical margin
dc.subject	treatment response
dc.subject	tumor biopsy
dc.subject.classification	7 INGENIERÍA Y TECNOLOGÍA
dc.title	Her-2 positive mucinous carcinoma breast cancer, case report
dc.type	Artículo
refterms.dateFOA	2018-10-18T15:34:03Z

Files

Original bundle

Now showing 1 - 1 of 1

Name:: 1-s2.0-S2210261217306776.pdf
Size:: 2.16 MB
Format:: Adobe Portable Document Format

Download

Collections

Artículo